Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chung A Won is a traditional Korean polyherbal formulation (Hanbang) primarily developed and investigated for the treatment of postmenopausal osteoporosis. The formulation is typically composed of extracts from *Eucommia ulmoides* (Duchung), *Psoralea corylifolia* (Boh-gol-zhee), Walnut (*Juglans sinensis* or *regia*), and Ginger (*Zingiber officinale*). Its therapeutic mechanism involves a dual action on bone metabolism: it stimulates the differentiation of osteoblasts to promote bone formation and inhibits the activity of osteoclasts to reduce bone resorption. The formulation contains various bioactive phytochemicals, including phytoestrogens like bavachin, which act as estrogen receptor agonists to support bone mineral density. Clinical research, including a Phase 2 trial (NCT02592161) conducted at Daejeon University, has evaluated its efficacy in improving T-scores and alleviating bone loss symptoms in women over the age of 50.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chung A Won.